ALN ANG3
Alternative Names: ALN-ANG3Latest Information Update: 17 Dec 2025
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Regeneron Pharmaceuticals
- Class Cardiovascular therapies; Small interfering RNA
- Mechanism of Action ANGPTL3 protein expression inhibitors; RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 09 Dec 2025 Regeneron Pharmaceuticals plans a phase II ANCHOR-POC trial for Diabetic-nephropathies (Monotherapy, Combination therapy) in December 2025 (NCT07271186)
- 27 Jun 2024 Phase-I clinical trials in Metabolic disorders (In volunteers) in New Zealand (SC) (NCT06452771)
- 13 Jun 2024 Preclinical trials in Unspecified in USA (SC), prior to June 2024